Evidence map›Paper›PMID 31598115›Full record

ArticleContrast media & molecular imaging2019

Ningning Song, Lingzhou Zhao, Meilin Zhu, Jinhua Zhao

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contrast media & molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Frontiers in bioengineering and biotechnology · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ningning SongDepartment of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.ORCID 0000-0002-9294-0790
Lingzhou ZhaoDepartment of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.ORCID 0000-0003-4270-5335
Meilin ZhuSchool of Basic Medical Sciences, Ningxia Medical University, Yinchuan 750004, Ningxia, China.ORCID 0000-0001-8719-8934
Jinhua ZhaoDepartment of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.ORCID 0000-0002-8867-7985
Shanghai Jiao Tong University · CNNingxia Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple negative breast cancer (TNBC), the most aggressive breast cancer type, is associated with high mortality and recurrence rates. An active-targeted strategy based on homing peptides is an effective approach to diagnose and treat cancer as it can deliver imaging agents or therapeutic drugs into desired tissues and accumulate less into off-target tissues. As a homing peptide, LyP-1 has shown properties of targeting, internalization, and proapoptosis to TNBC. In the study, we designed a Technetium-99m- (

Indexed as

Fluorescein-5-isothiocyanatePeptides, CyclicRadiopharmaceuticalsTechnetiumAnimalsBiocompatible MaterialsCarcinomaCell Line, TumorDrug StabilityFemaleLymphatic MetastasisMammary Neoplasms, AnimalMice, Inbred BALB CMice, NudeMicroscopy, ConfocalNeoplasm TransplantationBiocompatible MaterialsFluorescein-5-isothiocyanateLyP-1 peptidePeptides, CyclicRadiopharmaceuticalsTechnetium

Identifiers

PMID31598115
PMCPMC6778934
OpenAlexW2976084826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.